A failure of forward translation? The case of neuroprotection

Abstract

More than half a century of research focused on ischemic brain injury mechanisms has failed to yield a widely accepted neuroprotective drug for the treatment of acute ischemic stroke (AIS). The absence of a therapeutic intervention targeted at neuroprotective mechanisms raises questions about the relevance of preclinical models in human stroke. Indeed, this failure of forward translation (traditional bench-to-bedside research) to bring candidate drugs into clinical use suggests that alternative or complementary approaches are needed. Here, we discuss the potential of reverse translational research - exploring a bedside-to-bench approach - utilizing big data genomics to discover novel AIS therapeutic targets. This approach might provide insights into new and old drug targets.

Keywords

Neruoprotection / acute ischemic stroke / genomics / NIH stroke scale

References

[1] GBD 2016 Neurology CollaboratorsGlobal, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016..Lancet Neurol18:459-480 PMCID:PMC6459001

[2] Johnson W,Owolabi M.Stroke: a global response is needed..Bull World Health Organ2016;94:634-634A PMCID:PMC5034645

[3] Albers GW,Kemp S.Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging..N Engl J Med2018;378:708-18 PMCID:PMC6590673

[4] Goyal M,van Zwam WH.Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials..Lancet2016;387:1723-31

[5] Jovin TG,Cobo E.Thrombectomy within 8 hours after symptom onset in ischemic stroke..N Engl J Med2015;372:2296-306

[6] Lee JM,Zipfel GJ.Brain tissue responses to ischemia..J Clin Invest2000;106:723-31 PMCID:PMC381398

[7] Lee JM,Choi DW.The changing landscape of ischaemic brain injury mechanisms..Nature1999;399:A7-14

[8] Chamorro Á.Neuroprotectants in the Era of Reperfusion Therapy..J Stroke2018;20:197-207 PMCID:PMC6007301

[9] O’Collins VE,Donnan GA,van der Worp BH.1,026 experimental treatments in acute stroke..Ann Neurol2006;59:467-77

[10] Degraba TJ.Why do neuroprotective drugs work in animals but not humans?.Neurologic Clinics2000;18:475-93

[11] Philip M,Fisher M.Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials..Stroke2009;40:577-81

[12] Schmidt-Pogoda A,Koecke MHM.Why most acute stroke studies are positive in animals but not in patients: a systematic comparison of preclinical, early phase, and phase 3 clinical trials of neuroprotective agents..Ann Neurol2020;87:40-51

[13] Ginsberg MD.Neuroprotection for ischemic stroke: past, present and future..Neuropharmacology2008;55:363-89 PMCID:PMC2631228

[14] Grupke S,Dobbs M,Fraser JF.Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview..Clin Neurol Neurosurg2015;129:1-9

[15] Herson PS.Animal models of stroke: translational potential at present and in 2050..Future Neurol2014;9:541-51 PMCID:PMC4266275

[16] Stroke Therapy Academic Industry Roundtable (STAIR)Recommendations for standards regarding preclinical neuroprotective and restorative drug development..Stroke1999;30:2752-8

[17] Feuerstein GZ,Krams M.Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke..J Cereb Blood Flow Metab2008;28:217-9

[18] Savitz SI.Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials..Ann Neurol2007;61:396-402

[19] Fisher M,Howells DW.Update of the stroke therapy academic industry roundtable preclinical recommendations..Stroke2009;40:2244-50 PMCID:PMC2888275

[20] Visscher PM,Zhang Q.10 years of GWAS discovery: biology, function, and translation..Am J Hum Genet2017;101:5-22 PMCID:PMC5501872

[21] DeAngelis MM,Morrison MA.Genetics of age-related macular degeneration (AMD)..Hum Mol Genet2017;26:R45-50 PMCID:PMC5886461

[22] Furey TS,Sheikh SZ.Redefining the IBDs using genome-scale molecular phenotyping..Nat Rev Gastroenterol Hepatol2019;16:296-311

[23] Zheng H,Wen H.Application of genome-wide association studies in coronary artery disease..Curr Pharm Des2019;25:4274-86

[24] Rohde K,la Cour Poulsen L,Kovacs P.Genetics and epigenetics in obesity..Metabolism2019;92:37-50

[25] Horwitz T,Chen Y,Liu C.A decade in psychiatric GWAS research..Mol Psychiatry2019;24:378-89 PMCID:PMC6372350

[26] Andrews SJ,Goate A.Interpretation of risk loci from genome-wide association studies of Alzheimer’s disease..Lancet Neurology2020;19:326-35

[27] Chen Q,Sun F.Finding genetic overlaps among diseases based on ranked gene lists..J Comput Biol2015;22:111-23 PMCID:PMC4326265

[28] Jhamb D,Hurle MR.Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities..Drug Discov Today2019;24:1232-6

[29] Parvathaneni V,Muth A.Drug repurposing: a promising tool to accelerate the drug discovery process..Drug Discov Today2019;24:2076-85

[30] Cook D,Alexander R.Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework..Nat Rev Drug Discov2014;13:419-31

[31] Nelson MR,Painter JL.The support of human genetic evidence for approved drug indications..Nat Genet2015;47:856-60

[32] Heitsch L,Carrera C.Early neurological change after ischemic stroke is associated with 90-day outcome..Stroke52:132-41 PMCID:PMC7769959

[33] Zaitlen N,Gur T,Halperin E.Leveraging genetic variability across populations for the identification of causal variants..Am J Hum Genet2010;86:23-33 PMCID:PMC2801753

[34] Cooper RS,Zhu X.Genome-wide association studies: implications for multiethnic samples..Hum Mol Genet2008;17:R151-5 PMCID:PMC2782359

[35] Morris AP.Transethnic meta-analysis of genomewide association studies..Genet Epidemiol2011;35:809-22 PMCID:PMC3460225

[36] Ibanez L,Carrera C.Multi-ancestry genetic study in 5,876 patients identifies an association between excitotoxic genes and early outcomes after acute ischemic stroke..medRxiv2020;2020 PMCID:PMC7654887

[37] Del-Aguila JL,Dube U.A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain..Alzheimers Res Ther2019;11:71 PMCID:PMC6689177

[38] Ge P,Dawson TM.PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease..Mol Neurodegener2020;15:20 PMCID:PMC7071653

[39] Zhong S.A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease..Biochem Pharmacol2019;164:188-204 PMCID:PMC6580420

[40] Hivert B,Agbam KN.ADAM22 and ADAM23 modulate the targeting of the Kv1 channel-associated protein LGI1 to the axon initial segment..J Cell Sci2019;132:jcs219774

[41] Lancaster E,Zhang J.ADAM23 is a negative regulator of K_v1.1/K_v1.4 potassium currents..Neurosci Lett2019;704:159-63

[42] van Sonderen A,Dalmau J.The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis..Nat Rev Neurol2017;13:290-301

[43] Petit-Pedrol M,Planagumà J.LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory..Brain2018;141:3144-59 PMCID:PMC6202570

[44] Fukata Y,Iwanaga T,Nicoll RA.Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission..Science2006;313:1792-5

[45] Koskinen LL,Weissl J.ADAM23 is a common risk gene for canine idiopathic epilepsy..BMC Genet2017;18:8 PMCID:PMC5282852

[46] Lovero KL,Granger AJ,Nicoll RA.The LGI1-ADAM22 protein complex directs synapse maturation through regulation of PSD-95 function..Proc Natl Acad Sci U S A2015;112:E4129-37 PMCID:PMC4522810

[47] Palmer CL,Henley JM.The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors..Pharmacol Rev2005;57:253-77 PMCID:PMC3314513

[48] Chamorro Á,Urra X.Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation..The Lancet Neurology2016;15:869-81

[49] Neuhaus AA,Hadley G.Neuroprotection in stroke: the importance of collaboration and reproducibility..Brain2017;140:2079-92

[50] Hasin Y,Lusis A.Multi-omics approaches to disease..Genome Biol2017;18:83 PMCID:PMC5418815